20 May 2013
Keywords: ImmunoCellular Therapeutics, Roche, Licensing, cancer
Article | 10 September 2009
USA-based ImmunoCellular Therapeutics says that it has entered into a research and license option agreement regarding its ICT-69 antibody with ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 September 2009
© 2013 thepharmaletter.com